KR910016915A - 과콜레스테롤혈증 치료제 - Google Patents

과콜레스테롤혈증 치료제 Download PDF

Info

Publication number
KR910016915A
KR910016915A KR1019910004292A KR910004292A KR910016915A KR 910016915 A KR910016915 A KR 910016915A KR 1019910004292 A KR1019910004292 A KR 1019910004292A KR 910004292 A KR910004292 A KR 910004292A KR 910016915 A KR910016915 A KR 910016915A
Authority
KR
South Korea
Prior art keywords
compound
atcc
pharmaceutically acceptable
effective amount
fungal growth
Prior art date
Application number
KR1019910004292A
Other languages
English (en)
Inventor
디. 버그스트롬 제임스
디. 헨센스 오토
후앙 리유안
씨. 오니시 자네트
엘. 징크 데보라
에프. 빌스 제랄드
날린 메리
에프. 바티잘 케네스
에이. 밀리간 제임스
로즈딜스키 월터
두프레스네 클라우드
티. 디에즈 마리아
Original Assignee
제임스 에프. 너턴
머크 앤드 캄파니, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/496,734 external-priority patent/US5132320A/en
Priority claimed from US07/625,572 external-priority patent/US5055487A/en
Application filed by 제임스 에프. 너턴, 머크 앤드 캄파니, 인코포레이티드 filed Critical 제임스 에프. 너턴
Publication of KR910016915A publication Critical patent/KR910016915A/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/90—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having two or more relevant hetero rings, condensed among themselves or with a common carbocyclic ring system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/14—Fungi; Culture media therefor
    • C12N1/145—Fungal isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/18—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin
    • C12P17/181—Heterocyclic compounds containing oxygen atoms as the only ring heteroatoms in the condensed system, e.g. Salinomycin, Septamycin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/645—Fungi ; Processes using fungi

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Environmental Sciences (AREA)
  • Agronomy & Crop Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Plant Pathology (AREA)
  • Pest Control & Pesticides (AREA)
  • Dentistry (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

내용 없음

Description

과콜레스테롤혈증 치료제
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도 및 제2도는 일반식(Ⅰ)의 화합물의 H NMR 스펙트럼이다.

Claims (13)

  1. 일반식(Ⅰ)의 화합물, 또는 Z1, Z2및 Z3중 적어도 하나가 수소인 경우 상기 화합물의 약제학적으로 허용되는 염.
    상기식에서, Z1, Z2및 Z3는 각각 독립적으로, a) H; b)a-5알킬; 및 c)i) 페닐, 및 ii) 메틸, 메톡시, 할로겐(Cl, Br, I, F)또는 하이드록시로 치환된 페닐로 구성된 그룹의 일원으로 치환된 C1-5알킬중에서 선택된다.
  2. 제1항에 있어서, 일반식(Ⅰ)의 상대적 배위가 하기와 같은 화합물.
  3. 제2항에 있어서, Z1, Z2및 Z3가 각각 수소인 화합물 또는 이의 약제학적으로 허용되는 염.
  4. 제2항에 있어서, Z1, Z2및 Z3가 각각 메틸인 화합물.
  5. 무독성의 치료학적 유효량의 제1항의 화합물 및 약제학적으로 허용되는 담체를 포함하는 약제학적 조성물.
  6. 과콜레스테롤혈증의 치료가 필요한 환자에게 무독성의 치료학적 유효량의 제1항의 화합물을 투여함을 특징으로 하여 과콜레스테롤혈증을 치료하는 방법.
  7. 하기 구조의 화합물을 회수가능한 양으로 생산할 수 있는, MF 5447(ATCC 20985)의 배양물 또는 이의 활성 돌연변이체.
  8. 하기 구조의 화합물을 회수가능한 양으로 생산할 수 있는, MF 5466(ATCC 20989)의 배양물 또는 이의 활성 돌연변이체.
  9. 하기 구조의 화합물을 형성시키기에 적합한 조건하에서, MF 5447(ATCC 20985)또는 이의 활성 돌연변이체를 배양하고 그 화합물을 회수함을 포함하는 하기 구조의 화합물을 제조하는 방법.
  10. 하기 구조의 화합물을 형성시키기에 적합한 조건하에서, MF 5466(ATCC 20989)또는 이의 활성 돌연변이체를 배양하고 그 화합물을 회수함을 포함하는 하기 구조의 화합물을 제조하는 방법.
  11. 진균성장을 제어할 영역에 항진균 유효량의 일반식(Ⅰ)의 화합물, 또는 Z1, Z2및 Z3중 적어도 하나가 수소인 경우 상기 화합물의 약제학적으로 허용되는 염을 적용시킴을 특징으로 하여 진균 성장을 억제하는 방법.
    상기식에서, Z1, Z2및 Z3는 각각 독립적으로 a) H; b)C1-5알킬; 및 C)i) 페닐, 및 ii) 메틸, 메톡시, 할로겐(Cl, Br, I, F)또는 하이드록시로 치환된 페닐로 구성된 그룹의 일원으로 치환된 C1-5알킬중에서 선택된다.
  12. 항진균 유효량의 제11항의 화합물을 경구, 전신 또는 비경구적으로 투여함을 특징으로 하는 진균 성장을 억제하는 치료가 필요한 살아있는 유기체에서 진균 성장을 억제하는 방법.
  13. 제12항에 있어서, 화합물이 하기 화합물(1) 및 (2)로 구성된 그룹중에서 선택되는 방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019910004292A 1990-03-21 1991-03-19 과콜레스테롤혈증 치료제 KR910016915A (ko)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US49673390A 1990-03-21 1990-03-21
US49674390A 1990-03-21 1990-03-21
US07/496,734 US5132320A (en) 1990-03-21 1990-03-21 Squalene synthetase inhibitors
US?496,733? 1990-03-21
US?496,734? 1990-03-21
US?496,743? 1990-03-21
US07/625,572 US5055487A (en) 1990-03-21 1990-12-11 Novel anti-fungal compounds
US?625,572? 1990-12-11

Publications (1)

Publication Number Publication Date
KR910016915A true KR910016915A (ko) 1991-11-05

Family

ID=27504382

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019910004292A KR910016915A (ko) 1990-03-21 1991-03-19 과콜레스테롤혈증 치료제

Country Status (14)

Country Link
EP (1) EP0448393A1 (ko)
JP (1) JPH04217986A (ko)
KR (1) KR910016915A (ko)
AU (1) AU640756B2 (ko)
CA (1) CA2038450A1 (ko)
CS (1) CS68891A2 (ko)
FI (1) FI911352A (ko)
HU (1) HUT61554A (ko)
IE (1) IE910935A1 (ko)
IL (1) IL97251A0 (ko)
NO (1) NO911122L (ko)
NZ (1) NZ237405A (ko)
PT (1) PT97068A (ko)
YU (1) YU48791A (ko)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL97535A0 (en) * 1990-03-21 1992-06-21 Merck & Co Inc Squalene synthetase inhibitor dioxabicyclo(1,2,3)octanes,their production and pharmaceutical compositions containing them
NZ239663A (en) * 1990-09-13 1993-07-27 Merck & Co Inc Ester derivatives of dioxabicyclo(3,2,1)-octane, medicaments, and a fungus which makes them
GB9100437D0 (en) * 1991-01-09 1991-02-20 Glaxo Group Ltd Chemical compounds
US5506262A (en) * 1991-05-10 1996-04-09 Merck & Co., Inc. Cholesterol lowering compounds
US5256689A (en) * 1991-05-10 1993-10-26 Merck & Co., Inc. Cholesterol lowering compounds
CA2071655A1 (en) * 1991-06-28 1992-12-29 Gerald F. Bills Sporormiella intermedia and processes therefrom
GB2261375A (en) * 1991-11-15 1993-05-19 Merck & Co Inc Inhibitors of farnesyl protein transferase as anti-cancer agents
US5294627A (en) * 1992-08-27 1994-03-15 Merck & Co., Inc. Directed biosynthesis of biologically active compounds
US5252471A (en) * 1992-03-09 1993-10-12 Merck & Co., Inc. Directed biosynthesis of cholesterol lowering compounds
GB9205136D0 (en) * 1992-03-10 1992-04-22 Glaxo Group Ltd Chemical compounds
GB9205140D0 (en) * 1992-03-10 1992-04-22 Glaxo Group Ltd Chemical compounds
EP0568946A1 (en) * 1992-05-08 1993-11-10 Takeda Chemical Industries, Ltd. Compound TAN-1607A, its derivatives, their production, and use thereof
US5283256A (en) * 1992-07-22 1994-02-01 Merck & Co., Inc. Cholesterol-lowering agents
US5322855A (en) * 1992-10-19 1994-06-21 Merck & Co., Inc. Cholesterol lowering compounds
US5332728A (en) * 1992-11-23 1994-07-26 Bristol-Myers Squibb Company Method for treating a fungal infection
US5447717A (en) * 1993-02-25 1995-09-05 Merck & Co., Inc. Cholesterol-lowering agents
WO1995004025A1 (fr) * 1993-07-29 1995-02-09 Chugai Seiyaku Kabushiki Kaisha Derive d'acide tricarboxylique a activite d'inhibition de la squalene-synthetase
US5783593A (en) * 1993-11-04 1998-07-21 Abbott Laboratories Inhibitors of squalene synthetase and protein farnesyltransferase
US5631401A (en) * 1994-02-09 1997-05-20 Abbott Laboratories Inhibitors of protein farnesyltransferase and squalene synthase
US5430055A (en) * 1994-04-08 1995-07-04 Pfizer Inc. Inhibitor of squalene synthase

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4871721A (en) * 1988-01-11 1989-10-03 E. R. Squibb & Sons, Inc. Phosphorus-containing squalene synthetase inhibitors
IL97535A0 (en) * 1990-03-21 1992-06-21 Merck & Co Inc Squalene synthetase inhibitor dioxabicyclo(1,2,3)octanes,their production and pharmaceutical compositions containing them
NZ239663A (en) * 1990-09-13 1993-07-27 Merck & Co Inc Ester derivatives of dioxabicyclo(3,2,1)-octane, medicaments, and a fungus which makes them

Also Published As

Publication number Publication date
AU640756B2 (en) 1993-09-02
NZ237405A (en) 1993-07-27
HUT61554A (en) 1993-01-28
PT97068A (pt) 1991-11-29
NO911122L (no) 1991-09-23
FI911352A (fi) 1991-09-22
YU48791A (sh) 1994-01-20
HU910929D0 (en) 1991-10-28
AU7370491A (en) 1991-10-03
JPH04217986A (ja) 1992-08-07
IE910935A1 (en) 1991-09-25
CS68891A2 (en) 1991-11-12
IL97251A0 (en) 1992-05-25
CA2038450A1 (en) 1991-09-22
NO911122D0 (no) 1991-03-20
FI911352A0 (fi) 1991-03-20
EP0448393A1 (en) 1991-09-25

Similar Documents

Publication Publication Date Title
KR910016915A (ko) 과콜레스테롤혈증 치료제
KR910016931A (ko) 과콜레스테린혈증 치료제
NO991700L (no) Benzimidazol-2-karbamater for behandling av virusinfeksjoner og cancer
MY119350A (en) Propiophenone derivatives and process for preparing the same
KR900006318A (ko) 피페리디닐 벤즈이미다졸
KR920006360A (ko) 스쿠알렌 합성효소 억제제
KR900008049A (ko) Bu-3608 항생제의 세린 동족체
GR3031029T3 (en) Process for the preparation of pharmaceutically active thiazolidine or oxazolidine compounds by a yeast reductase.
KR840007257A (ko) 레베카마이신과 그것의 제조방법
KR870005004A (ko) 마크롤라이드 항생물질 유도체
KR930007902A (ko) 아세틸렌 화합물
KR910016934A (ko) 트립토판 동족체 공급에 의한 레베카마이신 동족체
KR920002517A (ko) 칼모둘린 억제 특성을 갖는 벤즈히드릴 유도체 및 그의 제조방법
KR900016178A (ko) 2-치환 n,n'-디트리메톡시벤조일 피페라진, 그의 제조 방법 및 그를 함유하는 치료 조성물
NO178025C (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive (benzhydryloksyetylpiperidyl)alifatiske syrederivater
KR900004717A (ko) 이미다졸 부정맥증 치료제
KR890009901A (ko) 3-히드록시-2-(4-메톡시페닐)-5-(2-메틸아미노에틸)-2,3-디히드로-5h-1,5- 벤조티아제핀-4-온 유도체, 그의 제조 및 치료에의 이용
AU655869B2 (en) An amphoteric tricyclic compound
KR930017902A (ko) 살충제 화합물 및 그의 제조 방법
HK1003573A1 (en) New antibiotics of the mureidomycin group their preparation and their therapeutic use
KR940005279A (ko) 아미딘을 함유하는 약제학적 조성물 및 아미딘
KR880001630A (ko) 5-플루오로우라실 유도체 및 그의 용도
KR920002594A (ko) 5-이소티아졸아민 유도체
KR860002574A (ko) 항생물질 at 2433 복합체의 제조방법
AU677403B2 (en) Intermediates useful in the preparation of 2-tetrahydrofuranderivatives

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid